# Maze Therapeutics

> Clinical-stage biotech using human genetics to develop precision small-molecule medicines.

## Why it is interesting

Maze's Compass platform links genetic variants to druggable pathways — a16z joined ARCH and Third Rock as co-investors across $496M+ raised toward renal, cardio, and metabolic programs.

## Profile

- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series D (Dec 2024): $115M co-led by Frazier Life Sciences and Deep Track; a16z, ARCH, Third Rock, General Catalyst among existing investors (company IR)
- Series A (Feb 2019): $191M with ARCH, Third Rock, GV (company IR)
- Co-investors: ARCH, Third Rock, General Catalyst added; Frazier/Deep Track not in VCT directory (sources reviewed 2026-07-24)

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/arch-venture-partners
- https://venturecapitaltracker.com/fund/third-rock-ventures
- https://venturecapitaltracker.com/fund/general-catalyst

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/maze-therapeutics